Compare CNXN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNXN | ATAI |
|---|---|---|
| Founded | 1982 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1997 | 2025 |
| Metric | CNXN | ATAI |
|---|---|---|
| Price | $72.15 | $3.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.88 |
| AVG Volume (30 Days) | 82.1K | ★ 4.4M |
| Earning Date | 04-29-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | $6.24 | N/A |
| Revenue Next Year | $4.39 | N/A |
| P/E Ratio | $105.16 | ★ N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $54.97 | $2.00 |
| 52 Week High | $73.67 | $6.73 |
| Indicator | CNXN | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 69.54 | 38.88 |
| Support Level | $56.30 | $3.44 |
| Resistance Level | N/A | $4.20 |
| Average True Range (ATR) | 2.12 | 0.31 |
| MACD | 0.55 | -0.02 |
| Stochastic Oscillator | 84.19 | 0.42 |
PC Connection Inc is a provider of information technology solutions. It provides products such as computer systems, software and peripheral equipment, networking communications, and other products and accessories that company purchase from manufacturers and distributors. The company also offers services involving design, configuration, and implementation of IT solutions. It conducts business operations through three business segments namely Connection Business Solutions, Connection Enterprise Solutions, and Connection Public Sector Solutions. The company generates maximum revenue Connection Enterprise Solutions segment.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.